|
|
Article: Antegren's Miss In Crohn's Mars Respectable Earnings For Biogen.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Associate Managing Editor
Biogen Inc. and partner Elan Corp. plc released disappointing Phase III data on Antegren in an induction trial in Crohn's disease, dragging both companies' stocks down and overshadowing positive second-quarter figures for Biogen.
The Antegren trial, called Enact-1 (Evaluation of Natalizumab in Active Crohn's Disease Therapy-1), did not meet its primary endpoint of a response - a 70-point decrease in the Crohn's Disease Activity Index at week 10 - although it did show biological activity similar to what was seen in earlier Phase II work. Secondary endpoints were response and remission (an index score of less than or equal to ...